Plain-English translation of NCT07007364 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for early-stage oral squamous cell carcinoma (cancer in the mouth). Patients receive low-dose radiation therapy combined with a medication called adebrelimab and chemotherapy (albumin-bound paclitaxel) for two cycles before surgery. After surgery, some patients may receive additional immunotherapy cycles, depending on how well the treatment worked.
Currently, people with early mouth cancer often need surgery followed by removal of neck lymph nodes to check for cancer spread. Researchers hope that giving this medication and radiation before surgery will shrink tumors enough that some patients can avoid the lymph node removal surgery, reducing side effects while maintaining or improving survival.
You likely qualify if…
You likely don't qualify if…
You would receive two cycles of combined radiation, immunotherapy, and chemotherapy over several weeks as an outpatient. About 3–4 weeks after this treatment, you would have surgery to remove the cancer. Researchers would then evaluate how well the treatment worked. If your cancer shows a complete response, you would continue with 6 more cycles of immunotherapy alone. Throughout the trial, you would have blood tests, imaging scans, and regular clinic visits to monitor your health and how well you're tolerating the treatment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China